| Literature DB >> 32218300 |
Luigi Vimercati1, Lucia Bisceglia2, Domenica Cavone1, Antonio Caputi1, Luigi De Maria1, Maria Celeste Delfino1, Vincenzo Corrado1, Giovanni Maria Ferri1.
Abstract
A follow-up study of a cohort of workers from a coke plant compared with a control group from the same industrial area was conducted in 2019. The recruitment and environmental and biomarker measurements were performed during 1993/1994. The environmental concentrations of polycyclic aromatic hydrocarbons (PAH), B(a)P, pyrene and nitro-PAH were measured. Personal data were collected via an individual semi-structured questionnaire by a trained physician. All biomarkers were measured after a specific blood drawing for every test. Significant risks (ORs) were observed for nitro-PAH (≥0.12 µg/m3) [OR = 7.96 (1.01-62.82)], urinary 1-hydroxypyrene (1-OHpy) (≥0.99 µmoles/moles of creatinine) [OR = 11.71 (1.47-92.90)], PAH DNA adducts (P32) (≥2.69 adducts/108 nucleotides) [OR = 5.46 (1.17-25.58)], total nitro-PAH hemoglobin adducts (≥161.68 fg/µg of Hb) [OR = 5.92 (1.26-27.86)], sister chromatid exchange (SCE) with TCR (≥377.84 SCE/cell chromosomes) [OR = 13.06 (3.95-93.10)], sister chromatid exchange with T (≥394.72 total SCE) [OR = 13.06 (3.95-93.10)], and sister chromatid exchange with X (≥8.19 mean SCE) [OR = 13.06 (3.95-93.10)]. Significant risk of death for all causes and chromosomal aberrations (48 h) (OR = 7.19 [1.19-43.44]) or micronuclei in culture at 48 h (OR = 3.86 [1.04-14.38]) were also found.Entities:
Keywords: biomarkers; cohort; coke plant; occupational exposure; sister chromatid exchange; total nitro-PAH hemoglobin adducts; urinary 1-hydroxypyrene (1-OHpy), PAH DNA adducts; vital status
Year: 2020 PMID: 32218300 PMCID: PMC7178092 DOI: 10.3390/ijerph17072199
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Frequency distribution of the main individual characteristics by study groups.
| Variables | Total Workers | Coke Plant Workers | Non-Coke Plant Workers | ||||
|---|---|---|---|---|---|---|---|
|
| % |
| % |
| % | ||
| Education | Elementary school | 58 | 47.15 | 57 | 54.81 | 1 | 5.26 |
| Secondary school | 48 | 39.02 | 36 | 34.62 | 12 | 63.16 | |
| High school | 15 | 12.20 | 10 | 9.62 | 5 | 26.32 | |
| University | 2 | 1.63 | 1 | 0.96 | 1 | 5.26 | |
| Work shift | Day | 29 | 23.58 | 10 | 9.62 | 19 | 100 |
| Day, Afternoon | 21 | 17.07 | 21 | 20.19 | 0 | 0 | |
| Day, afternoon, Night | 73 | 59.35 | 73 | 70.19 | 0 | 0 | |
| Residency | Taranto Borgo | 12 | 9.76 | 10 | 9.62 | 2 | 10.53 |
| Taranto Tamburi-State | 12 | 9.76 | 12 | 11.54 | 0 | 0 | |
| Taranto San Vito | 33 | 26.83 | 24 | 23.08 | 9 | 47.37 | |
| Taranto Province | 66 | 53.66 | 58 | 55.77 | 8 | 42.11 | |
| Pack-years | 0 | 28 | 22.76 | 20 | 19.23 | 8 | 42.11 |
| 0.1–17.10 | 53 | 43.09 | 44 | 42.31 | 9 | 47.37 | |
| >17.10 | 42 | 34.15 | 40 | 38.46 | 2 | 10.53 | |
| Broiled foods | No | 8 | 6.50 | 8 | 7.69 | 0 | 0 |
| Yes | 115 | 93.50 | 96 | 92.31 | 19 | 100 | |
| Age at visit | ≤35 years | 9 | 7.32 | 5 | 4.81 | 4 | 21.05 |
| 36–45 years | 57 | 46.34 | 50 | 48.08 | 7 | 36.84 | |
| >45 years | 49 | 39.84 | 49 | 47.12 | 8 | 42.11 | |
| Age 2019 | ≤55 years | 2 | 1.63 | 0 | 0 | 2 | 10.53 |
| 56–65 years | 35 | 28.46 | 24 | 23.08 | 11 | 57.89 | |
| >65 years | 86 | 69.92 | 80 | 76.92 | 6 | 31.5 | |
| Job length at visit | ≤10 years | 21 | 17.07 | 18 | 17.31 | 3 | 15.79 |
| 11–20 years | 67 | 54.47 | 53 | 50.96 | 14 | 73.68 | |
| >20 years | 35 | 28.46 | 33 | 31.73 | 2 | 10.53 | |
| Total workers | 123 | 100 | 104 | 100 | 19 | 100 | |
Vital status of the study groups at the end of study (2020).
| Coke Oven Workers | Non-Coke Oven Workers | Total | |
|---|---|---|---|
| Alive | 75 | 19 | 94 |
| * Deaths for all the causes | 16 | 0 | 16 |
| Lost at follow up (OUTRES) | 13 | 0 | 13 |
| Total | 104 | 19 | 123 |
* non cancer diseases (n.6), cancer diseases (n. 8), unknown diseases (n.2).
Characteristics of Study Death Subject.
| ID | Names | Year of Death | Age at Death | Latency | Cause of Death |
|---|---|---|---|---|---|
| 1 | A.C. | 2013 | 62 | 20 | Cancer |
| 2 | M.C. | 2018 | 70 | 25 | Unknown |
| 3 | S.P. | 2009 | 61 | 16 | Cancer |
| 4 | S.V. | 2016 | 66 | 23 | Cancer |
| 5 | C.A. | 2015 | 62 | 22 | Non Cancer |
| 6 | C.L. | 2019 | 74 | 26 | Cancer |
| 7 | B.G. | 2017 | 66 | 24 | Non Cancer |
| 8 | P.G.V. | 2013 | 67 | 20 | Non Cancer |
| 9 | R.G. | 2000 | 56 | 7 | Cancer |
| 10 | C.A. | 2008 | 64 | 15 | Cancer |
| 11 | M.G. | 2014 | 67 | 21 | Cancer |
| 12 | G.M. | 2012 | 66 | 19 | Cancer |
| 13 | I.F. | 2008 | 50 | 15 | Non Cancer |
| 14 | C.C. | 2002 | 50 | 9 | Unknown |
| 15 | M.E. | 2002 | 55 | 9 | Non Cancer |
| 16 | V.M. | 2012 | 68 | 19 | Non Cancer |
Environmental exposure concentrations, biomarkers measurements, and polymorphisms frequencies by study groups.
| Coke Plant Workers | Non-Coke Plant Workers | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| VARIABLES (LN) |
| Means | s.d. |
| Means | s.d. | t |
| |
| Environmental exposure | Benzo[a]pyrene (B[a]p) | 104 | 0.034 | 0.780 | 19 | 0.230 | 0.630 | −1.020 | 0.150 |
| Polycyclic Aromatic Hydrocarbons (PAH) | 104 | 2.770 | 0.490 | 19 | 2.330 | 0.650 | 3.420 | 0 | |
| Pyrene | 104 | 0.029 | 0.910 | 19 | −0.008 | 0.520 | 0.170 | 0.420 | |
| Nitro PAH | 104 | −2.650 | 0.850 | 19 | −4.820 | 0 | 10.980 | 0 | |
| Benzene | 34 | 3.320 | 0.540 | ||||||
| Nitrosamines | 34 | −4.560 | 0.210 | ||||||
| Aliphatic Amines | 91 | 0.830 | 1.110 | ||||||
| Aromatic Amines | 34 | 2.300 | 0 | ||||||
| Biomarkers of exposure | Urinary Hydroxypyrene (p_ 1_OH) | 83 | −0.120 | 1.040 | 18 | −2.740 | 0.710 | 10.110 | 0 |
| Urinary Cotinine | 54 | −2.060 | 1.820 | ||||||
| Biomarkers of Biologic Effective Dose | PAH DNA Adducts (P32) | 99 | 0.800 | 0.540 | 17 | 0.400 | 0.320 | 2.890 | 0.002 |
| Cells with Diagonal Radioactive Zone (DRZ) | 85 | 0.079 | 0.980 | 2 | 0.320 | 0.360 | −0.340 | 0.360 | |
| 2-Amino Fluorene Hemoglobin Adducts | 85 | 2.870 | 1.680 | 11 | 1.200 | 1.110 | 3.110 | 0.001 | |
| 9-Amino Phenanthrene Hemoglobin Adducts | 73 | 2.370 | 1.240 | 10 | 1.930 | 1.190 | 1.040 | 0.150 | |
| 3-Amino Fluoranthene Hemoglobin Adducts | 57 | 2.340 | 1.190 | 6 | 1.780 | 1.220 | 1.090 | 0.130 | |
| 1-Amino Pyrene Hemoglobin Adducts | 97 | 3.090 | 1.750 | 17 | 2.400 | 1.460 | 1.540 | 0.060 | |
| 6-Amino Chrysene Hemoglobin Adducts | 54 | 2.250 | 1.430 | 4 | 1.140 | 0.960 | 1.510 | 0.068 | |
| Total Nitro-PAH Hemoglobin Adducts | 102 | 4.360 | 1.560 | 19 | 3.220 | 1.520 | 2.900 | 0.002 | |
| Biomarkers of effects | Cells with Chromosomal Aberrations in culture at 48 h | 49 | 0.270 | 0.380 | 13 | 0.210 | 0.330 | 0.560 | 0.280 |
| Cells with Chromosomal Aberrations (unstable[Cu] e stable[Cs]) at 48 h | 38 | 0.160 | 0.330 | 5 | 0.130 | 0.300 | 0.170 | 0.420 | |
| Cells (‰) with Micronuclei in culture at 48 h | 91 | 0.390 | 0.570 | 18 | 0.210 | 0.710 | 1.190 | 0.110 | |
| Cells with Chromosomal Aberrations in culture at 72 h | 45 | 0.240 | 0.360 | 12 | 0.230 | 0.340 | 0.150 | 0.430 | |
| Cells with Chromosomal Aberrations (Instable(Cu) e stable(Cs)) a 72 ore | 40 | 0.170 | 0.370 | 8 | 0.250 | 0.350 | −0.560 | 0.280 | |
| Cells (‰) with Micronuclei in culture at 72 h | 92 | 0.590 | 0.500 | 19 | 0.500 | 0.390 | 0.700 | 0.240 | |
| Cells with Chromosomal Aberrations in culture at 72 h with Cytocala B | 92 | 2.590 | 0.970 | 19 | 3.040 | 0.470 | −1.970 | 0.025 | |
| Sister Chromatid Exchange (SCE) with TCR | 32 | 5.420 | 0.990 | 15 | 5.500 | 0.780 | −0.260 | 0.390 | |
| Sister Chromatid Exchange (SCE) with T | 32 | 5.570 | 0.910 | 15 | 5.350 | 0.920 | 0.770 | 0.220 | |
| Sister Chromatid Exchange (SCE) with X | 32 | 2.020 | 0.300 | 15 | 1.870 | 0.120 | 1.790 | 0.039 | |
| Alteration of Urinary DNA (Flow Cytofluorometry) | 67 | 1.640 | 0.350 | 7 | 1.720 | 0.430 | −0.540 | 0.290 | |
| Mutations with Unscheduled DNA Synthesis (UDS) | 88 | 6.510 | 0.780 | 6 | 8.430 | 0.260 | −5.940 | 0 | |
| Cells with Thioguanine Resistance (TGR) | 46 | 0.480 | 0.880 | 18 | 0.570 | 1.070 | −0.340 | 0.360 | |
| Cells with Cloning Efficiency (CE) | 47 | 2.200 | 0.840 | 18 | 2.290 | 0.540 | −0.400 | 0.340 | |
| Cells with Mutant Frequencies (MF) | 48 | 2.770 | 1.040 | 18 | 2.770 | 0.990 | −0.010 | 0.490 | |
|
|
|
|
|
|
|
|
|
| |
| Biomarkers of genetical susceptibility | MSPI (CYPA1A variant Restriction enzyme polymorphism) | 76 | 16 | 76.190 | 18 | 5 | 23.810 | 0.370 | 0.530 |
| ILEVAL (CYPA1A variant Isoleucine-Valine polymorphisms) | 76 | 14 | 82.350 | 18 | 3 | 17.650 | 0.030 | 0.860 | |
| GSTM1 (Glutathione S-Transferase Mu 1 gene polymorphisms) | 76 | 42 | 79.250 | 18 | 11 | 20.750 | 0.200 | 0.650 | |
| NAT2 (N-acetyltransferase 2 gene polymorphisms) | 73 | 49 | 90.740 | 11 | 5 | 9.260 | 1.950 | 0.162 | |
Figure 1Correlation matrix of ln transformed variables.
Distribution of adjusted estimates of risks (*ORs) to observe values of different biomarkers higher to the 66th percentile among coke oven plant workers versus non-coke oven plant workers.
| Variables | ORs | LCI (95%) | UCI (95%) | |
|---|---|---|---|---|
| Environmental exposure | Benzo[a]pyrene (B[a]p) [≥1.40 µg/m3] | 0.61 | 0.22 | 1.71 |
| Polycyclic Aromatic Hydrocarbons (PAH) [≥15.18 µg/m3] | 1.21 | 0.42 | 3.49 | |
| Pyrene [≥1.60 µg/m3] | 1.90 | 0.61 | 5.93 | |
| Nitro PAH [≥0.12 µg/m3] | 7.96 | 1.01 | 62.82 | |
| Biomarkers of exposure | Urinary Hydroxypyrene (p_ 1_OH) [≥0.99 µmoles/moles of creatinine] | 11.71 | 1.47 | 92.90 |
| Urinary Cotinine [≥0.38 µmoles/moles of creatinine] | 0.06 | 0.00 | 0.54 | |
| Biomarkers of Biologic Effective Dose | PAH DNA Adducts (P32) [≥2.69 Adducts/108 nucleotides] | 5.46 | 1.17 | 25.58 |
| Cells with Diagonal Radioactive Zone (DRZ) [≥1.37 Adducts/108 nucleotides] | 3.36 | 0.89 | 12.65 | |
| 2-Amino Fluorene Hemoglobin Adducts [≥42.02 fg/µg of Hb] | 1.18 | 0.42 | 3.30 | |
| 9-Amino Phenanthrene Hemoglobin Adducts [≥16.00 fg/µg of Hb] | 0.78 | 0.27 | 2.23 | |
| 3-Amino Fluoranthene Hemoglobin Adducts [≥17.24 fg/µg of Hb] | 0.48 | 0.15 | 1.52 | |
| 1-Amino Pyrene Hemoglobin Adducts [≥41.70 fg/µg of Hb] | 1.40 | 0.47 | 4.13 | |
| 6-Amino Chrysene Hemoglobin Adducts [≥16.00 fg/µg of Hb] | 0.41 | 0.12 | 1.38 | |
| Total Nitro-PAH Hemoglobin Adducts [≥161.68 fg/µg of Hb] | 5.92 | 1.26 | 27.86 | |
| Biomarkers of effects | Cells with Chromosomal Aberrations in culture at 48 h [≥1 Total cells with CA] | 0.54 | 0.18 | 1.60 |
| Cells with Chromosomal Aberrations (unstable[Cu] e stable[Cs]) at 48 h [≥1 Total cells with CA] | 2.22 | 0.72 | 6.86 | |
| Cells (‰) with Micronuclei in culture at 48 h [≥2.00 cells (‰) with micronuclei] | 1.34 | 0.47 | 3.82 | |
| Cells with Chromosomal Aberrations in culture at 72 h [≥1 Total cells with CA] | 0.57 | 0.20 | 1.62 | |
| Cells with Chromosomal Aberrations ((Instable(Cu) e stable [Cs]) a 72 ore [≥1 Total cells with CA] | 1.20 | 0.43 | 3.36 | |
| Cells (‰) with Micronuclei in culture at 72 h [≥2.33 cells (‰) with micronuclei] | 2.08 | 0.67 | 6.42 | |
| Cells with Chromosomal Aberrations in culture at 72 h with Cytocala B [≥22.60 cells (‰) with micronuclei/total cells] | 0.59 | 0.20 | 1.76 | |
| Sister Chromatid Exchange (SCE) with TCR [≥377.84 sce/cells chromosomes] | 13.06 | 3.95 | 43.16 | |
| Sister Chromatid Exchange (SCE) with T [≥394.72 total sce] | 13.06 | 3.95 | 43.16 | |
| Sister Chromatid Exchange (SCE) with X [≥8.19 mean sce] | 13.06 | 3.95 | 43.16 | |
| Alteration of Urinary DNA (Flow CytoFluorimetry) [≥5.90] | 0.30 | 0.09 | 1.02 | |
| Mutations with Unscheduled DNA Synthesis (UDS) [≥1149.72 cpm/106 cells] | 0.03 | 0 | 0.21 | |
| Cells with Thioguanine Resistance (TGR) [≥2.36 TGR cells/106 cells] | 2.05 | 0.73 | 5.77 | |
| Cells with Cloning Efficiency (CE) [≥13.30%] | 1.90 | 0.67 | 5.34 | |
| Cells with Mutant Frequencies (MF) [≥25.48 MF/106 cells] | 2.42 | 0.85 | 6.87 | |
| Biomarkers of genetical susceptibility | MSPI (CYPA1A variant Restriction enzyme Polymorphism) [Presence] | 0.71 | 0.21 | 2.41 |
| ILEVAL (CYPA1A variant Isoleucine-Valine polymorphisms) [Presence] | 1.42 | 0.34 | 5.85 | |
| GSTM1 (Glutathione S-Transferase Mu 1 gene polymorphisms) [Presence] | 0.78 | 0.21 | 2.80 | |
| NAT2 (N-acetyltransferase 2 gene polymorphisms) [Presence] | 3.02 | 0.79 | 11.56 | |
Distribution of adjusted estimates of risks (*ORs) to observe values of different biomarkers higher to the 66th centile by vital status (deaths for all the causes).
| Variables | ORs | LCI (95%) | UCI (95%) | |
|---|---|---|---|---|
| Environmental exposure | Benzo[a]pyrene (B[a]p) [≥1.40 µg/m3] | 0.72 | 0.18 | 2.88 |
| Polycyclic Aromatic Hydrocarbons (PAH) [≥15.18 µg/m3] | 0.82 | 0.14 | 4.82 | |
| Pyrene [≥1.60 µg/m3] | 0.44 | 0.09 | 2.04 | |
| Nitro PAH [≥0.12 µg/m3] | 0.74 | 0.16 | 3.45 | |
| Biomarkers of exposure | Urinary Hydroxypyrene (p_ 1_OH) [≥0.99 µmoles/moles of creatinine] | 1.15 | 0.35 | 3.72 |
| Urinary Cotinine [≥0.38 µmoles/moles of creatinine] | 1.56 | 0.36 | 6.75 | |
| Biomarkers of Biologic Effective Dose | PAH DNA Adducts (P32) [≥2.69 Adducts/108 nucleotides] | 0.90 | 0.27 | 2.97 |
| Cells with Diagonal Radioactive Zone (DRZ) [≥1.37 Adducts/108 nucleotides] | 0.66 | 0.18 | 2.36 | |
| 2-Amino Fluorene Hemoglobin Adducts [≥42.02 fg/µg of Hb] | 2.49 | 0.72 | 8.61 | |
| 9-Amino Phenanthrene Hemoglobin Adducts [≥16.00 fg/µg of Hb] | 1.59 | 0.47 | 5.36 | |
| 3-Amino Fluoranthene Hemoglobin Adducts [≥17.24 fg/µg of Hb] | 0.53 | 0.15 | 1.83 | |
| 1-Amino Pyrene Hemoglobin Adducts [≥41.70 fg/µg of Hb] | 1.35 | 0.40 | 4.48 | |
| 6-Amino Chrysene Hemoglobin Adducts [≥16.00 fg/µg of Hb] | 0.83 | 0.22 | 3.02 | |
| Total Nitro-PAH Hemoglobin Adducts [≥161.68 fg/µg of Hb] | 2.38 | 0.69 | 8.24 | |
| Biomarkers of effects | Cells with Chromosomal Aberrations in culture at 48 h [≥1 Total cells with CA] | 7.19 | 1.19 | 43.44 |
| Cells with Chromosomal Aberrations (unstable[Cu] e stable[Cs]) at 48 h [≥1 Total cells with CA] | 0.44 | 0.13 | 1.50 | |
| Cells (‰) with Micronuclei in culture at 48 h [≥2.00 cells (‰) with micronuclei] | 3.86 | 1.04 | 14.38 | |
| Cells with Chromosomal Aberrations in culture at 72 h [≥1 Total cells with CA] | 0.43 | 0.12 | 1.52 | |
| Cells with Chromosomal Aberrations ((Instable(Cu) e stable [Cs]) a 72 ore [≥1 Total cells with CA] | 0.93 | 0.27 | 3.14 | |
| Cells (‰) with Micronuclei in culture at 72 h [≥2.33 cells (‰) with micronuclei] | 0.79 | 0.24 | 2.60 | |
| Cells with Chromosomal Aberrations in culture at 72 h with Cytocala B [≥22.60 cells (‰) with micronuclei/total cells] | 1.14 | 0.33 | 3.85 | |
| Sister Chromatid Exchange (SCE) with TCR [≥377.84 sce/cells chromosomes] | 1.54 | 0.29 | 8.10 | |
| Sister Chromatid Exchange (SCE) with T [≥394.72 total sce] | 3.81 | 0.44 | 32.95 | |
| Sister Chromatid Exchange (SCE) with X [≥8.19 mean sce] | 1.70 | 0.32 | 8.90 | |
| Alteration of Urinary DNA (Flow Cytofluorimetry) [≥5.90] | 0.36 | 0.10 | 1.27 | |
| Mutations with Unscheduled DNA synthesis (UDS) [≥1149.72 cpm/106 cells] | 1.55 | 0.48 | 5.05 | |
| Cells with Thioguanine Resistance (TGR) [≥2.36 TGR cells/106 cells] | 2.41 | 0.55 | 10.57 | |
| Cells with Cloning Efficiency (CE) [≥13.30 %] | 2.90 | 0.63 | 19.85 | |
| Cells with Mutant Frequencies (MF) [≥25.48 MF/106 cells] | 3.12 | 0.57 | 16.82 | |
| Biomarkers of genetical susceptibility | MSPI (CYPA1A variant Restriction enzyme Polymorphism) [Precence] | 0.63 | 0.09 | 4.33 |
| ILEVAL (CYPA1A variant Isoleucine-Valine polymorphisms) [Presence] | 0.14 | 0.00 | 2.47 | |
| GSTM1 (Glutathione S-Transferase Mu 1 gene polymorphisms) [Presence] | 3.24 | 0.52 | 20.00 | |
| NAT2 (N-acetyltransferase 2 gene polymorphisms) [Presence] | 0.56 | 0.12 | 2.63 | |
Distributions of adjusted estimates of risks (*ORs) to observe values of different biomarkers higher to the 66th centile by cancer death.
| VARIABLES | ORs | LCI (95%) | UCI (95%) | |
|---|---|---|---|---|
| Environmental exposure | Benzo[a]pyrene (B[a]p) [≥1.40 µg/m3] | 0.77 | 0.11 | 5.05 |
| Polycyclic Aromatic Hydrocarbons (PAH) [≥15.18 µg/m3] | 1.11 | 0.11 | 11.32 | |
| Pyrene [≥1.60 µg/m3] | 0.39 | 0.04 | 3.75 | |
| Nitro PAH [≥0.12 µg/m3] | 1.61 | 0.23 | 10.93 | |
| Biomarkers of exposure | Urinary Hydroxypyrene (p_ 1_OH) [≥0.99 µmoles/moles of creatinine] | 0.37 | 0.06 | 2.16 |
| Urinary Cotinine [≥0.38 µmoles/moles of creatinine] | 0.63 | 0.12 | 3.14 | |
| Biomarkers of Biologic Effective Dose | PAH DNA Adducts (P32) [≥2.69 Adducts/108 nucleotides] | 0.36 | 0.06 | 2.10 |
| Cells with Diagonal Radioactive Zone (DRZ) [≥1.37 Adducts/108 nucleotides] | 0.51 | 0.09 | 2.87 | |
| 2-Amino Fluorene Hemoglobin Adducts [≥42.02 fg/µg of Hb] | 3.60 | 0.62 | 20.86 | |
| 9-Amino Phenanthrene Hemoglobin Adducts [≥16.00 fg/µg of Hb] | 2.70 | 0.46 | 15.66 | |
| 3-Amino Fluoranthene Hemoglobin Adducts [≥17.24 fg/µg of Hb] | 0.89 | 0.18 | 4.36 | |
| 1-Amino Pyrene Hemoglobin Adducts [≥41.70 fg/µg of Hb] | 1.61 | 0.34 | 7.49 | |
| 6-Amino Chrysene Hemoglobin Adducts [≥16.00 fg/µg of Hb] | 0.66 | 0.13 | 3.28 | |
| Total Nitro-PAH Hemoglobin Adducts [≥161.68 fg/µg of Hb] | 1.70 | 0.35 | 8.04 | |
| Biomarkers of effects | Cells with Chromosomal Aberrations in culture at 48 h [≥1 Total cells with CA] | 6.61 | 0.66 | 65.41 |
| Cells with Chromosomal Aberrations (unstable[Cu] e stable[Cs]) at 48 h [≥1 Total cells with CA] | 0.08 | 0.00 | 0.81 | |
| Cells (‰) with Micronuclei in culture at 48 h [≥2.00 cells (‰) with micronuclei] | 3.67 | 0.65 | 20.62 | |
| Cells with Chromosomal Aberrations in culture at 72 h [≥1 Total cells with CA] | 0.93 | 0.19 | 4.58 | |
| Cells with Chromosomal Aberrations ((Instable(Cu) e stable [Cs]) a 72 ore [≥1 Total cells with CA] | 1.56 | 0.32 | 7.59 | |
| Cells (‰) with Micronuclei in culture at 72 h [≥2.33 cells (‰) with micronuclei] | 1.26 | 0.28 | 5.63 | |
| Cells with Chromosomal Aberrations in culture at 72 h with Cytocala B [≥22.60 cells (‰) with micronuclei/total cells] | 0.92 | 0.18 | 4.63 | |
| Sister Chromatid Exchange (SCE) with TCR [≥377.84 sce/cells chromosomes] | 0.69 | 0.11 | 4.09 | |
| Sister Chromatid Exchange (SCE) with T [≥394.72 total sce] | 1.86 | 0.20 | 17.09 | |
| Sister Chromatid Exchange (SCE) with X [≥8.19 mean sce] | 0.75 | 0.12 | 4.39 | |
| Alterazioni del DNA Urinario (Flow Cytofluorimetry) [≥5.90] | 0.40 | 0.08 | 1.90 | |
| Mutations with Unscheduled DNA Synthesis (UDS) [≥1149.72 cpm/106 cells] | 2.19 | 0.45 | 10.49 | |
| Cells with Thioguanine Resistance (TGR) [≥2.36 TGR cells/106 cells] | 2.92 | 0.32 | 26.58 | |
| Cells with Cloning Efficiency (CE) [≥13.30 %] | 2.90 | 0.32 | 25.68 | |
| Cells with Mutant Frequencies (MF) [≥25.48 MF/106 cells ] | 2.38 | 0.25 | 22.70 | |
| Biomarkers of genetical susceptibility | MSPI (CYPA1A variant Restriction enzyme Polymorphism) [Precence] | - | - | - |
| ILEVAL (CYPA1A variant Isoleucine-Valine polymorphisms) [Presence] | - | - | - | |
| GSTM1 (Glutathione S-Transferase Mu 1 gene polymorphisms) [Presence] | - | - | - | |
| NAT2 (N-acetyltransferase 2 gene polymorphisms) [presence] | 0.84 | 0.03 | 23.18 | |
* All these estimates (ORs) were adjusted by pack years, night shift work, residence in Taranto Tamburi and charcoal-broiled food intake.